More tools:Markets·Screener·Research·Chat

Senti Biosciences, Inc. Common Stock (SNTI) Financial Statements

Senti Biosciences, Inc. Common Stock
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG010WX8056
XNAS · usd
0.32▼ 0.02 (-5.05%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value—
Trailing P/E—
Price / Sales
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt—
Trading Information
Previous Close0.33
Day's Range0.31 – 0.34
52-Week Range0.31 – 2.88
Volume397.6K
Avg Volume194.4K
Share Statistics
Shares Outstanding
Employees39
ExchangeXNAS
Listed2022-06-09
Share count as of July 31, 2026
Loading Income Statement…
Key questions about Senti Biosciences, Inc. Common Stock (SNTI)
What is Senti Biosciences, Inc. Common Stock's Market Cap?
Senti Biosciences, Inc. Common Stock's Market Cap is $9.8M, based on as-reported figures from SEC (XBRL) filings.
What is Senti Biosciences, Inc. Common Stock's Price / Sales?
Senti Biosciences, Inc. Common Stock's Price / Sales is 178.8×, based on as-reported figures from SEC (XBRL) filings.
What is Senti Biosciences, Inc. Common Stock's Revenue (TTM)?
Senti Biosciences, Inc. Common Stock's Revenue (TTM) is $55.0K, based on as-reported figures from SEC (XBRL) filings.
What is Senti Biosciences, Inc. Common Stock's Net Income (TTM)?
Senti Biosciences, Inc. Common Stock's Net Income (TTM) is -$49.6M, based on as-reported figures from SEC (XBRL) filings.
What is Senti Biosciences, Inc. Common Stock's EBITDA?
Senti Biosciences, Inc. Common Stock's EBITDA is -$51.5M, based on as-reported figures from SEC (XBRL) filings.
What is Senti Biosciences, Inc. Common Stock's Diluted EPS (TTM)?
Senti Biosciences, Inc. Common Stock's Diluted EPS (TTM) is -1.59, based on as-reported figures from SEC (XBRL) filings.
What is Senti Biosciences, Inc. Common Stock's EBITDA Margin?
Senti Biosciences, Inc. Common Stock's EBITDA Margin is -93703.6%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Collaboration revenue - related party——
YoY growth————
Operating expenses:
Research and development (including related party costs of $3,516 and $3,586 for the three months ended June 30, 2026 and 2025, respectively, and $3,798 and $7,656 for the six months ended June 30, 2026 and 2025, respectively)
General and administrative
Gain on lease modification——
Total operating expenses
% of revenue85329.4%28950.0%——
Loss from operations
% of revenue-85229.4%-28850.0%——
Other income:
Interest income
GeneFab sublease income - related party——
Change in fair value of convertible notes - related party—
Other income, net
Total other income
Net loss
% of revenue-75000.0%-26381.3%——
Net loss per share, basic (in dollars per share)
Net loss per share, diluted (in dollars per share)